에 대한 최신 뉴스 Edwards Lifesciences (NYSE:EW) 주식

Edwards Lifesciences

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.

Large Cap

News

Movers

DELL

LULU

MBLY

MEDP

SMCI

STLA

이들 12개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 에드워드 라이프사이언스(NYSE:EW)의 주가는 회사가 예상보다 나쁜 2분기 매출 실적을 보고하고 예상치보다 낮은 3분기 가이던스를 발표한 후 28.05% 급락했다. 회사는 또한 제나밸브(JenaValve)와 엔도트로닉스(Endotronix)를 인수했다. 몇몇 분석가들은 가격 전망을 대폭 낮췄다.

포드, 스텔란티스 및 델은 지난주 최악의 성과를 보인 12개 대형주 중 일부 (7월 21일부터 7월 27일)

Equities

Previews

Tech

Trading Ideas

ABBV

AGYS

ASML

BJRI

CHKP

CHTR

CMCSA

DECK

GATX

GOOG

GOOGL

JNPR

NFLX

NXPI

ODFL

ORLY

SKYW

SPOT

TSLA

VRSN

S&amp;P 500 기업들 중 약 14%가 6월 분기 실적을 발표했으며, 더 넓은 지수를 구성하는 기업들의 혼합 실적 성장률은 여전히 ​​양호하다. 이번 주에는 기술 보고 시즌이 공식적으로 시작될 것이며, 이는 최근 주에 가파른 하락세를 보인 시장의 향방을 잠재적으로 결정할 수 있다.

테슬라, 알파벳, GM 및 포드가 이번 주 실적 발표 주도하며 상승세 유지 위해 고군분투

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences Corp

iShares MSCI Australia Index Fund

East West Bancorp Inc

EAST WEST BANKING CORP by EAST WEST BANKING CORPORATION

iShares MSCI Canada Index Fund

ENERGY WORLD CORP LTD by Energy World Corp. Ltd.

Energy World Corp Ltd

European Wax Center, Inc. - Class A Common Stock

European Wax Center Inc

iShares Inc iShares MSCI Sweden ETF

Global X Funds Emerging Mkts Internet & E- Commerce ETF (New)

iShares MSCI Germany Index Fund

EAT WELL INVT GROUP INC by Eat Well Investment Group Inc.

Eat Well Investment Group Inc

iShares Trust MSCI Germany Small-Cap ETF

iShares MSCI Hong Kong Index Fund

iShares Inc iShares MSCI Italy ETF

EDINBURGH WORLDWIDE INVES by Edinburgh Worldwide Investment Trust plc

iShares MSCI Japan Index Fund

iShares MSCI Japan Value ETF

iShares Inc iShares MSCI Belgium ETF

EARTHWORKS ENTMT NEW by Earthworks Entertainment, Inc.

Earthworks Entertainment Inc

iShares Inc iShares MSCI Switzerland ETF

EWELLNESS HEALTHCARE CORP by eWellness Healthcare Corp

eWellness Healthcare Corp

Merion Inc

iShares MSCI Malaysia Index Fund

iShares MSCI Netherlands Index Fund

iShares Inc iShares MSCI Austria ETF

EASTWOOD BIO-MED CDA INC by Eastwood Bio-Med CDA Inc.

Eastwood Bio-Medical Canada Inc

iShares Inc iShares MSCI Spain ETF

EMERGING WORLD PHARMA INC by Emerging World Pharma, Inc.

Emerging World Pharma Inc

EAST WEST PETE ORD by East West Petroleum Corp.

East West Petroleum Corp

iShares MSCI France Index Fund

EWORLD COMPANIES INC by eWorld Companies, Inc.

eWorld Companies Inc

iShares Inc iShares MSCI Singapore ETF

EWSB BANCORP INC by EWSB Bancorp, Inc.

ISH S&P EQ WGHT US ETF

iShares Inc iShares MSCI Taiwan ETF

Energy Web Token

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics Inc

iShares MSCI United Kingdom ETF

Ishares MSCI United Kingdom Small Cap ETF

ProShares UltraShort MSCI Japan

iShares Inc iShares MSCI Mexico ETF

SPDR S&P Emerging Markets Small Cap ETF

iShares Inc iShares MSCI South Korea ETF

iShares Inc iShares MSCI Brazil ETF

iShares MSCI Brazil Small-Cap ETF

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$30.00</td>
<td>$65.0K</td>
<td>37.5K</td>
<td>2.1K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/27/24</td>
<td>$70.00</td>
<td>$26.2K</td>
<td>814</td>
<td>482</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$130.00</td>
<td>$25.3K</td>
<td>972</td>
<td>303</td>
</tr>
<tr>
<td>EW</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$67.50</td>
<td>$196.0K</td>
<td>7</td>
<td>201</td>
</tr>
<tr>
<td>EXAS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$62.50</td>
<td>$90.0K</td>
<td>1.0K</td>
<td>200</td>
</tr>
<tr>
<td>ILMN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$128.00</td>
<td>$32.6K</td>
<td>6</td>
<td>200</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$315.00</td>
<td>$105.3K</td>
<td>561</td>
<td>174</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$155.00</td>
<td>$55.5K</td>
<td>0</td>
<td>150</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$380.00</td>
<td>$98.7K</td>
<td>10</td>
<td>57</td>
</tr>
<tr>
<td>RPRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$20.00</td>
<td>$50.2K</td>
<td>43</td>
<td>54</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option trade with bullish sentiment. It expires in 485 day(s) on January 16, 2026. Parties traded 200 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $65.0K, with a price of $325.0 per contract. There were 37533 open contracts at this strike prior to today, and today 2165 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a put option sweep with bullish sentiment. It expires in 9 day(s) on September 27, 2024. Parties traded 104 contract(s) at a $70.00 strike. This particular put needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $26.2K, with a price of $252.0 per contract. There were 814 open contracts at this strike prior to today, and today 482 contract(s) were bought and sold. 
• Regarding SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we observe a call option trade with bullish sentiment. It expires in 30 day(s) on October 18, 2024. Parties traded 59 contract(s) at a $130.00 strike. The total cost received by the writing party (or parties) was $25.3K, with a price of $430.0 per contract. There were 972 open contracts at this strike prior to today, and today 303 contract(s) were bought and sold. 
• For EW (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), we notice a put option trade that happens to be neutral, expiring in 485 day(s) on January 16, 2026. This event was a transfer of 200 contract(s) at a $67.50 strike. The total cost received by the writing party (or parties) was $196.0K, with a price of $980.0 per contract. There were 7 open contracts at this strike prior to today, and today 201 contract(s) were bought and sold. 
• For EXAS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), we notice a put option trade that happens to be bullish, expiring in 121 day(s) on January 17, 2025. This event was a transfer of 200 contract(s) at a $62.50 strike. The total cost received by the writing party (or parties) was $90.0K, with a price of $450.0 per contract. There were 1039 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• Regarding ILMN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), we observe a call option sweep with bearish sentiment. It expires in 2 day(s) on September 20, 2024. Parties traded 102 contract(s) at a $128.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $32.6K, with a price of $320.0 per contract. There were 6 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option sweep with bearish sentiment. It expires in 121 day(s) on January 17, 2025. Parties traded 70 contract(s) at a $315.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $105.3K, with a price of $1505.0 per contract. There were 561 open contracts at this strike prior to today, and today 174 contract(s) were bought and sold. 
• Regarding ALGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>), we observe a put option trade with bullish sentiment. It expires in 211 day(s) on April 17, 2025. Parties traded 150 contract(s) at a $155.00 strike. The total cost received by the writing party (or parties) was $55.5K, with a price of $370.0 per contract. There were 0 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option sweep that happens to be bearish, expiring in 275 day(s) on June 20, 2025. This event was a transfer of 30 contract(s) at a $380.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $98.7K, with a price of $3290.0 per contract. There were 10 open contracts at this strike prior to today, and today 57 contract(s) were bought and sold. 
• For RPRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>), we notice a call option trade that happens to be bullish, expiring in 211 day(s) on April 17, 2025. This event was a transfer of 54 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $50.2K, with a price of $930.0 per contract. There were 43 open contracts at this strike prior to today, and today 54 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ALGN

AMGN

EXAS

ILMN

MRNA

RPRX

SRPT

10 Health Care Stocks With Whale Alerts In Today's Session

Jefferies analyst Matthew Taylor downgrades Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) from Buy to Hold and lowers the price target from $85 to $70.

Downgrades

Price Target

Analyst Ratings

Jefferies Downgrades Edwards Lifesciences to Hold, Lowers Price Target to $70

Rumors

Watching Edwards Lifesciences; Traders Circulate Unconfirmed M&A Blog Comments Suggesting The Co Is Engaged In Takeover Chatter

Truist Securities analyst Richard Newitter maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Hold and lowers the price target from $82 to $71.

Truist Securities Maintains Hold on Edwards Lifesciences, Lowers Price Target to $71

Oppenheimer analyst Suraj Kalia maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Outperform and maintains $90 price target.

Oppenheimer Maintains Outperform on Edwards Lifesciences, Maintains $90 Price Target

Investors with a lot of money to spend have taken a bullish stance on Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with EW, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for Edwards Lifesciences.
This isn't normal.
The overall sentiment of these big-money traders is split between 100% bullish and 0%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $41,878, and 7, calls, for a total amount of $298,360.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $67.5 to $75.0 for Edwards Lifesciences over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Edwards Lifesciences options trades today is 5795.75 with a total volume of 14,415.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Edwards Lifesciences's big money trades within a strike price range of $67.5 to $75.0 over the last 30 days.
<h3>Edwards Lifesciences Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726087538_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>EW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$1.9</td>
<td>$1.7</td>
<td>$1.75</td>
<td>$70.00</td>
<td>$94.3K</td>
<td>2.3K</td>
<td>539</td>
</tr>
<tr>
<td>EW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$0.8</td>
<td>$0.55</td>
<td>$0.55</td>
<td>$70.00</td>
<td>$47.7K</td>
<td>4.1K</td>
<td>894</td>
</tr>
<tr>
<td>EW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$4.8</td>
<td>$4.6</td>
<td>$4.6</td>
<td>$67.50</td>
<td>$41.8K</td>
<td>269</td>
<td>1</td>
</tr>
<tr>
<td>EW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$0.9</td>
<td>$0.8</td>
<td>$0.8</td>
<td>$70.00</td>
<td>$36.7K</td>
<td>4.1K</td>
<td>3.7K</td>
</tr>
<tr>
<td>EW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$0.6</td>
<td>$0.25</td>
<td>$0.25</td>
<td>$75.00</td>
<td>$32.4K</td>
<td>16.5K</td>
<td>1.5K</td>
</tr>
</tbody>
</table>

<h3>About Edwards Lifesciences</h3>
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
Having examined the options trading patterns of Edwards Lifesciences, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Edwards Lifesciences Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 4,306,276, the EW's price is up by 1.65%, now at $68.25. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 42 days.</li>
</ul>
<h3>Expert Opinions on Edwards Lifesciences</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $78.33333333333333.
<ul>
<li>Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Edwards Lifesciences, targeting a price of $80. </li>
<li>Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on Edwards Lifesciences with a target price of $75. </li>
<li>Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for Edwards Lifesciences, targeting a price of $80. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Edwards Lifesciences options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Markets

Decoding Edwards Lifesciences's Options Activity: What's the Big Picture?

UBS analyst Danielle Antalffy maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Neutral and lowers the price target from $90 to $75.

UBS Maintains Neutral on Edwards Lifesciences, Lowers Price Target to $75

Barclays analyst Matt Miksic maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Overweight and lowers the price target from $90 to $80.

Barclays Maintains Overweight on Edwards Lifesciences, Lowers Price Target to $80

Ratings for Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) were provided by 19 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">10</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $83.32, a high estimate of $110.00, and a low estimate of $70.00. This current average represents a 15.39% decrease from the previous average price target of $98.47. 
<img src="https://www.benzinga.com/files/images/story/2024/1725890462_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of Edwards Lifesciences's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$91.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Joshua Jennings</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$70.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$76.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Pito Chickering</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$85.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$85.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$82.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$70.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$77.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$73.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Travis Steed</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$72.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$106.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$91.00</td>
<td>$89.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Edwards Lifesciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Edwards Lifesciences compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Edwards Lifesciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Edwards Lifesciences's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EW/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Edwards Lifesciences analyst ratings.</a>
<h2>About Edwards Lifesciences</h2>
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
<h3>Edwards Lifesciences: A Financial Overview</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Edwards Lifesciences showcased positive performance, achieving a revenue growth rate of 6.98% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 26.43%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Edwards Lifesciences's ROE stands out, surpassing industry averages. With an impressive ROE of 5.03%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Edwards Lifesciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.69%, the company showcases efficient use of assets and strong financial health.
Debt Management: Edwards Lifesciences's debt-to-equity ratio is below the industry average. With a ratio of 0.09, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 19 Ratings For Edwards Lifesciences

Wells Fargo analyst Larry Biegelsen maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Overweight and lowers the price target from $90 to $80.

Wells Fargo Maintains Overweight on Edwards Lifesciences, Lowers Price Target to $80

Emerging Market ETFs

Buybacks

ETFs

Edwards Lifesciences Completes $4.2B Sale Of Critical Care To BD, Announces $1B Share Repurchase, And Board Authorizes Additional $1.5B For Future Buybacks

Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) today announced the results from the RHEIA Trial, a first-of-its-kind trial focused exclusively on outcomes for women receiving transcatheter aortic valve implantation (TAVI). Presenting one-year results during a Hot Line session at the ESC Congress 2024, investigators reported superior outcomes for women receiving the Edwards SAPIEN 3 Ultra or SAPIEN 3 Ultra RESILIA valves as compared to those receiving surgical aortic valve replacement (SAVR).

Reported Earlier, Edwards Lifesciences RHEIA Trial Discloses TAVI Outcomes for Women With SAPIEN 3 Valves

Edwards Lifesciences's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) short percent of float has risen 3.92% since its last report. The company recently reported that it has 6.34 million shares sold short, which is 1.06% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Edwards Lifesciences Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725037211_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Edwards Lifesciences has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Edwards Lifesciences's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Edwards Lifesciences's peer group average for short interest as a percentage of float is 4.58%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Edwards Lifesciences's Recent Short Interest

Deep-pocketed investors have adopted a bearish approach towards Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in EW usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Edwards Lifesciences. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 22% leaning bullish and 66% bearish. Among these notable options, 4 are puts, totaling $197,095, and 5 are calls, amounting to $166,123.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $60.0 to $77.5 for Edwards Lifesciences during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Edwards Lifesciences's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Edwards Lifesciences's substantial trades, within a strike price spectrum from $60.0 to $77.5 over the preceding 30 days.
<h3>Edwards Lifesciences Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724950158_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>EW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$0.3</td>
<td>$0.2</td>
<td>$0.3</td>
<td>$60.00</td>
<td>$73.7K</td>
<td>1.2K</td>
<td>13.2K</td>
</tr>
<tr>
<td>EW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$0.3</td>
<td>$0.25</td>
<td>$0.25</td>
<td>$60.00</td>
<td>$60.3K</td>
<td>1.2K</td>
<td>2.4K</td>
</tr>
<tr>
<td>EW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$0.85</td>
<td>$0.8</td>
<td>$0.85</td>
<td>$77.50</td>
<td>$46.8K</td>
<td>231</td>
<td>555</td>
</tr>
<tr>
<td>EW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$1.0</td>
<td>$0.95</td>
<td>$0.95</td>
<td>$75.00</td>
<td>$38.4K</td>
<td>10.5K</td>
<td>5.9K</td>
</tr>
<tr>
<td>EW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$1.25</td>
<td>$1.1</td>
<td>$1.25</td>
<td>$67.50</td>
<td>$32.2K</td>
<td>1.6K</td>
<td>260</td>
</tr>
</tbody>
</table>

<h3>About Edwards Lifesciences</h3>
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
In light of the recent options history for Edwards Lifesciences, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Edwards Lifesciences</h3>
<ul>
<li>Currently trading with a volume of 2,843,521, the EW's price is up by 3.47%, now at $71.03. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 55 days.</li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Edwards Lifesciences, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Edwards Lifesciences's Options Frenzy: What You Need to Know

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/16/24</td>
<td>$29.00</td>
<td>$46.5K</td>
<td>31.3K</td>
<td>38.7K</td>
</tr>
<tr>
<td>IBRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$4.00</td>
<td>$97.6K</td>
<td>250</td>
<td>10.0K</td>
</tr>
<tr>
<td>VRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$25.00</td>
<td>$43.7K</td>
<td>1.4K</td>
<td>1.1K</td>
</tr>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$17.50</td>
<td>$38.0K</td>
<td>3.2K</td>
<td>954</td>
</tr>
<tr>
<td>NBIX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$150.00</td>
<td>$45.6K</td>
<td>782</td>
<td>321</td>
</tr>
<tr>
<td>EW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$67.50</td>
<td>$29.9K</td>
<td>768</td>
<td>104</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/23/24</td>
<td>$126.00</td>
<td>$56.4K</td>
<td>8</td>
<td>86</td>
</tr>
<tr>
<td>BPMC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$105.00</td>
<td>$42.3K</td>
<td>417</td>
<td>58</td>
</tr>
<tr>
<td>EXAS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$50.00</td>
<td>$67.5K</td>
<td>488</td>
<td>16</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option trade with neutral sentiment. It expires in 3 day(s) on August 16, 2024. Parties traded 1500 contract(s) at a $29.00 strike. The total cost received by the writing party (or parties) was $46.5K, with a price of $31.0 per contract. There were 31318 open contracts at this strike prior to today, and today 38747 contract(s) were bought and sold. 
• For IBRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>), we notice a call option trade that happens to be bearish, expiring in 66 day(s) on October 18, 2024. This event was a transfer of 2169 contract(s) at a $4.00 strike. The total cost received by the writing party (or parties) was $97.6K, with a price of $45.0 per contract. There were 250 open contracts at this strike prior to today, and today 10038 contract(s) were bought and sold. 
• Regarding VRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>), we observe a call option sweep with bearish sentiment. It expires in 3 day(s) on August 16, 2024. Parties traded 199 contract(s) at a $25.00 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $43.7K, with a price of $220.0 per contract. There were 1424 open contracts at this strike prior to today, and today 1129 contract(s) were bought and sold. 
• Regarding SAVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>), we observe a put option sweep with bearish sentiment. It expires in 157 day(s) on January 17, 2025. Parties traded 40 contract(s) at a $17.50 strike. This particular put needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $38.0K, with a price of $951.0 per contract. There were 3205 open contracts at this strike prior to today, and today 954 contract(s) were bought and sold. 
• Regarding NBIX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>), we observe a call option trade with bullish sentiment. It expires in 38 day(s) on September 20, 2024. Parties traded 30 contract(s) at a $150.00 strike. The total cost received by the writing party (or parties) was $45.6K, with a price of $1520.0 per contract. There were 782 open contracts at this strike prior to today, and today 321 contract(s) were bought and sold. 
• Regarding EW (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), we observe a call option trade with bullish sentiment. It expires in 94 day(s) on November 15, 2024. Parties traded 65 contract(s) at a $67.50 strike. The total cost received by the writing party (or parties) was $29.9K, with a price of $460.0 per contract. There were 768 open contracts at this strike prior to today, and today 104 contract(s) were bought and sold. 
• Regarding MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we observe a put option trade with bearish sentiment. It expires in 10 day(s) on August 23, 2024. Parties traded 47 contract(s) at a $126.00 strike. The total cost received by the writing party (or parties) was $56.4K, with a price of $1202.0 per contract. There were 8 open contracts at this strike prior to today, and today 86 contract(s) were bought and sold. 
• Regarding BPMC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>), we observe a put option trade with bearish sentiment. It expires in 66 day(s) on October 18, 2024. Parties traded 29 contract(s) at a $105.00 strike. The total cost received by the writing party (or parties) was $42.3K, with a price of $1460.0 per contract. There were 417 open contracts at this strike prior to today, and today 58 contract(s) were bought and sold. 
• For EXAS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), we notice a call option trade that happens to be neutral, expiring in 157 day(s) on January 17, 2025. This event was a transfer of 50 contract(s) at a $50.00 strike. The total cost received by the writing party (or parties) was $67.5K, with a price of $1350.0 per contract. There were 488 open contracts at this strike prior to today, and today 16 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BPMC

IBRX

NBIX

SAVA

VRNA

9 Health Care Stocks Whale Activity In Today's Session

Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) has outperformed the market over the past 15 years by 6.11% on an annualized basis producing an average annual return of 17.72%. Currently, Edwards Lifesciences has a market capitalization of $36.60 billion. 
Buying $100 In EW: If an investor had bought $100 of EW stock 15 years ago, it would be worth $1,147.73 today based on a price of $60.75 for EW at the time of writing.
<h3>Edwards Lifesciences's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722960013_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Edwards Lifesciences 15 Years Ago Would Be Worth Today

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">BIMI Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIMI#NASDAQ">BIMI</a>)</h3>
<ul>
<li>On May 20, BIMI announced the receipt of a delinquency compliance alert notice from Nasdaq.  The company's stock fell around 68% over the past five days and has a <a href="https://www.benzinga.com/quote/BIM">52-week low of $0.24</a>.</li>
<li>RSI Value: 24.62</li>
<li>BIMI Price Action: Shares of BIMI Holdings closed at $0.42 on Wednesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent073124&amp;t=be2bearmibe3na1">trend in DXCM stock</a>.</li>
</ul>
<h3 class="wp-block-heading">Edwards Lifesciences Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>)&nbsp;</h3>
<ul>
<li>On July 24, Edwards Lifesciences reported worse-than-expected second-quarter sales results and issued third-quarter guidance below estimates. Also, the company acquired JenaValve and Endotronix.. The company's stock fell around 30% over the past month. It &lt;a href=&#8221;https://www.benzinga.com/quote/EW&#8221;&gt;&lt;em&gt; has a 52-week low &lt;/em&gt;&lt;/a&gt; of $58.93.</li>
<li>RSI Value: 22.55</li>
<li>EW Price Action: Shares of Edwards Lifesciences closed at $63.05 on Wednesday.</li>
<li><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent073124&amp;t=be2bearmibe3na1">Benzinga Pro&#8217;s real-time newsfeed</a> alerted to latest EW news.</li>
</ul>
<h3 class="wp-block-heading">Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</h3>
<ul>
<li>Merck reported better-than-expected second-quarter earnings and sales results on Tuesday. The company posted quarterly sales of $16.1 billion, up 7% year-over-year, beating the consensus estimate of $15.84 billion. Excluding the impact of foreign exchange, sales increased 11%. Merck reported adjusted EPS of $2.28, a shift from an EPS loss of $(2.06), beating the consensus of $2.15. The company's shares fell around 12% over the past month and has a 52-week &lt;a href=&#8221;https://www.benzinga.com/quote/MRK&#8221;>&lt;em> low of $99.14.&lt;/em>&lt;/a></li>
<li>RSI Value: 28.20</li>
<li>MRK Price Action: Shares of Merck rose 0.1% to close at $113.13 on Wednesday.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40092288/nasdaq-settles-higher-as-nvidia-records-best-session-since-february-fear-greed-index-now-in-neutral">Nasdaq Settles Higher As Nvidia Records Best Session Since February: Fear &amp; Greed Index Now In &#8216;Neutral&#8217; Zone As Investor Sentiment Improves</a></li>
</ul>

Long Ideas

BIMI

Top 3 Health Care Stocks That Are Set To Fly This Quarter

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said he likes Blackstone Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>). &#8220;They have a lot of great companies in house that are going to do <a href="https://www.benzinga.com/news/earnings/24/07/39839457/blackstone-q2-earnings-miss-stock-dips-as-costs-rise">very well,&#8221; he added</a>.
On July 18, Blackstone reported second-quarter fiscal year 2024 adjusted revenues of $2.796 billion, beating the consensus of $2.619 billion.
When asked about Borr Drilling Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BORR#NYSE">BORR</a>), Cramer said he always goes with the best, which is Schlumberger NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>).
On May 23, Borr Drilling reported better-than-expected first-quarter sales results and raised its dividend.
Lowe&#8217;s Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) is the kind of stock that should be bought right here, right now ahead of the Federal Reserve's rate cut cycle. &#8220;I would pick some up tomorrow,&#8221; he added.
On May 31, the company declared a quarterly cash dividend of $1.15 per share, payable Aug. 7 to shareholders of record as of July 24.
&#8220;I was mystified and surprised at that conference call, which was absolutely terrible, Cramer said about DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>). &#8220;I think Abbott (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) is a better play.&#8221;
On July 25, DexCom reported worse-than-expected second-quarter revenue results and issued weak revenue guidance.
When asked about Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>), he said, &#8220;They're two different things. Marvell the stock is probably being hurt, but Marvell the company, Matt Murphy [Chairman and CEO at Marvell] is doing a terrific job. I actually would own the stock.&#8221;
On July 30, the company introduced its Structera line of Compute Express Link (CXL) devices, designed to address memory performance and scaling challenges in general-purpose servers for cloud data centers.
The &#8220;Mad Money&#8221; host recommended selling Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>).
Joby Aviation will release its second quarter financial results after the closing bell on Wednesday, Aug. 7.
When asked about Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), he said, &#8220;You want to swap over to Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>).&#8221;
On July 24, Edwards Lifesciences reported worse-than-expected second-quarter sales results and issued third-quarter guidance below estimates. Also, the company acquired JenaValve and Endotronix.
Price Action:
<ul>
<li>Borr Drilling shares rose 2.3% to settle at $6.60 on Tuesday.</li>
<li>Marvell shares fell 2.6% to close at $62.80 on Tuesday.</li>
<li>Joby Aviation shares fell 1.9% to close at $6.09.</li>
<li>Blackstone shares rose 0.3% to settle at $141.34.</li>
<li>Dexcom rose 3.3% to close at $69.70 during Tuesday's session.</li>
<li>Edwards Lifesciences shares fell 0.2% to settle at $63.64 on Tuesday.</li>
<li>Lowe&#8217;s gained 0.7% to close at $241.40 on Tuesday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/40059087/nasdaq-tumbles-amid-decline-in-tech-stocks-greed-index-moves-to-fear-zone">Nasdaq Tumbles As Microsoft, Nvidia And Other Tech Stocks Decline: Greed Index Moves To &#8216;Fear&#8217; Zone</a></li>
</ul>
Photo: Shutterstock

BORR

DXCM

JOBY

MRVL

Jim Cramer Says This Home Improvement Chain Is A Buy Ahead Of Fed Rate Cut Cycle: 'I Would Pick Some Up Tomorrow'

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. `
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Edwards Lifesciences Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>)</h3>
<ul>
<li>On July 24, Edwards Lifesciences reported worse-than-expected second-quarter sales results and issued third-quarter guidance below estimates. Also, the company acquired JenaValve and Endotronix. The company's stock fell around 27% over the past five days and has a <a href="https://www.benzinga.com/quote/EW">52-week low of $58.93</a> &lt;/em>&lt;/a>.</li>
<li>RSI Value: 24.03</li>
<li>EW Price Action: Shares of Edwards Lifesciences fell 0.2% to close at $63.64 on Tuesday.</li>
<li><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent073124&amp;t=be2bearmibe3na1">Benzinga Pro's real-time newsfeed</a> alerted to latest EW news.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent073124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="671" height="755" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/31072942/Screenshot-2024-07-31-at-4.59.34-PM.png" alt="" class="wp-image-467205" style="width:418px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/31072942/Screenshot-2024-07-31-at-4.59.34-PM.png 671w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/31072942/Screenshot-2024-07-31-at-4.59.34-PM-267x300.png 267w" sizes="(max-width: 671px) 100vw, 671px" /></a></figure>
<h3 class="wp-block-heading">DexCom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>)&nbsp;&nbsp;</h3>
<ul>
<li>On July 25, DexCom reported worse-than-expected second-quarter revenue results and issued weak revenue guidance. "While Dexcom advanced several key strategic initiatives in the second quarter, our execution did not meet our high standards," said Kevin Sayer, Dexcom's CEO. "We have a unique opportunity to serve millions of more customers around the world with our differentiated product portfolio and we are taking action to improve our execution and best position ourselves for continued long-term growth." The company's stock fell around 38% over the past five days. It <a href="https://www.benzinga.com/quote/DXCM">has a 52-week low</a> of $62.34.</li>
<li>RSI Value: 20.25</li>
<li>DXCM Price Action: Shares of DexCom gained 3.3% to close at $69.70 on Tuesday.</li>
<li>Benzinga Pro's charting tool helped identify the <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent073124&amp;t=be2bearmibe3na1">trend in DXCM stock</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent073124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="687" height="716" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/31073105/Screenshot-2024-07-31-at-5.00.38-PM.png" alt="" class="wp-image-467207" style="width:497px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/31073105/Screenshot-2024-07-31-at-5.00.38-PM.png 687w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/31073105/Screenshot-2024-07-31-at-5.00.38-PM-288x300.png 288w" sizes="(max-width: 687px) 100vw, 687px" /></a></figure>
<h3 class="wp-block-heading">Biomx Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHGE#NYSE">PHGE</a>)</h3>
<ul>
<li>On July 29, BiomX announced NYSE American acceptance of plan to regain listing compliance. The company's stock dipped around 43% over the past month and has a 52-week l<a href="https://www.benzinga.com/quote/PHGE">ow of $0.19</a>.&lt;/em>&lt;/a></li>
<li>RSI Value: 24.28</li>
<li>PHGE Price Action: Shares of Biomx fell 8.5% to close at $0.19 on Tuesday.</li>
<li>Benzinga Pro's signals feature notified of a potential <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent073124&amp;t=be2bearmibe3na1">breakout in Biomx shares</a>.</li>
</ul>
<figure class="wp-block-image size-full"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent073124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="667" height="741" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/31073159/Screenshot-2024-07-31-at-5.01.33-PM.png" alt="" class="wp-image-467210" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/31073159/Screenshot-2024-07-31-at-5.01.33-PM.png 667w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/31073159/Screenshot-2024-07-31-at-5.01.33-PM-270x300.png 270w" sizes="(max-width: 667px) 100vw, 667px" /></a></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/40059087/nasdaq-tumbles-amid-decline-in-tech-stocks-greed-index-moves-to-fear-zone">Nasdaq Tumbles As Microsoft, Nvidia And Other Tech Stocks Decline: Greed Index Moves To &#8216;Fear&#8217; Zone</a></li>
</ul>

Pre-Market Outlook

PHGE

Top 3 Health Care Stocks That May Explode In Q3

Edwards Lifesciences's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) short percent of float has fallen 15.69% since its last report. The company recently reported that it has 7.70 million shares sold short, which is 1.29% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.16 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Edwards Lifesciences Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722355216_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Edwards Lifesciences has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Edwards Lifesciences's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Edwards Lifesciences's peer group average for short interest as a percentage of float is 4.85%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Edwards Lifesciences?

In a report released today, Richard Newitter from Truist Financial maintained a Hold rating on Edwards Lifesciences (EW – Research Report). The com...

Truist Financial Sticks to Its Hold Rating for Edwards Lifesciences (EW)

BNY Mellon Global Stock Fund Q2 2024 Commentary

Travis Steed, an analyst from Bank of America Securities, maintained the Hold rating on Edwards Lifesciences (EW – Research Report). The associated...

Hold Rating on Edwards Lifesciences Amidst Uncertain Growth and Market Dynamics

Edwards Lifesciences gains amid takeover speculation

In a report released yesterday, Matthew Taylor from Jefferies downgraded Edwards Lifesciences (EW – Research Report) to a Hold, with a price target...

Edwards Lifesciences: Hold Rating Amid TAVR Sector Challenges and Growth Constraints

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Edwards Lifesciences (EW – Research Report) yesterday and set a price target of $80....

Comments

Edwards Lifesciences

뉴스

에 대한 최신 뉴스 Edwards Lifesciences (NYSE:EW) 주식

월요일, 7월 29, 2024

일요일, 7월 21, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌